Repligen pilot study aims for better ID of pancreatic cancer

Thu, 07/21/2011 - 10:41am
Mass High Tech: The Journal of New England Technology

The first patient has been enrolled in a pilot study by Repligen Corp. for a compound that is intended to improve the detection of pancreatic cancer when using CT or MRI scans.

Ultimately, Waltham-based Repligen (Nasdaq: RGEN) will enroll up to 40 patients in the trial, all of whom have a known or suspected pancreatic mass, and the presence of a tumor will be confirmed by either surgery or biopsy. The pilot will be conducted at University Hospitals Case Medical Center in Cleveland, Ohio, which is affiliated with Case Western University.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.